A new study in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging lays the foundation for treating addiction with transcranial magnetic stimulation
In a study investigating the use of transcranial magnetic stimulation (TMS) for drug addiction, researchers at Medical University of South Carolina are the first to demonstrate that the noninvasive brain stimulation technique can dampen brain activity in response to drug cues in chronic alcohol users and chronic cocaine users. The findings are published in Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.
Although the last 50 years of clinical and preclinical research have demonstrated that addiction is a brain disease, there are still no neural circuit-based treatments for substance dependence or the brain functions involved in the disorder. “Here, for the first time, we demonstrate that a new non-invasive brain stimulation technique may be the first tool available to fill this critical void in addiction treatment development,” said senior author Colleen Hanlon, PhD.
Elevated brain activity in response to drug cues—referred to as cue reactivity—occurs with many types of drugs, including nicotine, alcohol, marijuana, and cocaine. Cue reactivity also predicts relapse in addiction, so treatment approaches targeting the neural circuitry related to cue reactivity may directly impact cue-induced relapse in patients.
“Therefore, these results have a tremendous potential to impact both basic discovery neuroscience as well as targeted clinical treatment development for substance dependence,” said Dr. Hanlon.
First author of the paper Tonisha Kearney-Ramos, PhD, and colleagues performed two independent studies at the same time, one involving 25 people with cocaine use disorder and the other involving 24 people with alcohol use disorder. The participants received one session of TMS, which targeted magnetic stimulation to circuitry critical for drug-taking behaviors—the ventromedial prefrontal cortex. The real stimulation session was compared against a sham session that mimicked the experience of receiving TMS without actual brain stimulation.
Brain imaging before and after TMS revealed that when alcohol users viewed images of alcohol-related cues, such as a liquor bottle, the single TMS session significantly reduced their drug cue reactivity. The same was true for cocaine users when viewing images of cocaine-related cues.
“Since cue reactivity has previously been associated with abstinence, these studies suggest a common mechanism for treatment effects across disorders, with fMRI serving as a promising neural readout of treatment effects,” said Cameron Carter, MD, Editor of Biological Psychiatry: Cognitive Neuroscience and Neuroimaging.
However, it is still unclear if the changes in brain activity observed in the study will translate to reduced drug or alcohol use. The participants did not report any changes in their drug or alcohol craving after TMS. The authors think that repeated sessions of the targeted stimulation may be needed to see changes in self-reported craving. The researchers hope to answer this question in an ongoing clinical trial involving multiple TMS sessions in cocaine users.
In addition to substance abuse, elevated cue-reactivity is a core symptom of many diseases, such as post-traumatic stress disorder, generalized anxiety disorder, traumatic brain injury, smoking, and obesity, said Dr. Hanlon. “Therefore, the treatment described in this manuscript may have implications far beyond the substance abuse field.”
The Latest on: Transcranial magnetic stimulation
via Google News
The Latest on: Transcranial magnetic stimulation
- Brain Stimulation Is the Future of Medicine on March 5, 2019 at 6:28 pm
I was just a zombie sleepwalking.” It wasn’t until she was 40 that Soloway found a better solution for her depression: transcranial magnetic stimulation (TMS). The procedure involves zapping ... […]
- Industry Meeting: Highlights and Insights in the TMS Field on March 5, 2019 at 12:23 pm
Anthony Trevor Barker, Ph.D., opened the meeting with his presentation, An A to Z of Transcranial Magnetic Stimulation – from Blue Skies Research to Clinical Tools, which reflected on his TMS ... […]
- BrainsWay Expands Intellectual Property Position by Obtaining Rights to Multi-Channel Transcranial Magnetic Stimulation Patent Portfolio on March 5, 2019 at 5:30 am
JERUSALEM, March 05, 2019 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (TASE: BRIN), a global leader in the advanced non-invasive treatment of brain disorders, today announced that it has acquired an ... […]
- Silicon Valley TMS Now Offering Cutting Edge Mental Health Technology for Obsessive-Compulsive Disorder (OCD) in Northern California on March 5, 2019 at 5:13 am
today announced that it will be one of the first practices in Northern California to offer its patients access to BrainsWay’s Deep Transcranial Magnetic Stimulation (Deep TMS) therapy for ... […]
- Priory’s Harley Street Wellbeing Centre to offer innovative drug-free approach to depression with the launch of magnetic stimulation therapy on March 5, 2019 at 4:09 am
Repetitive transcranial magnetic stimulation (rTMS) uses a pulsed magnetic field to induce a small electric current in part of the brain, which increases the connectivity of brain cells and is a highl... […]
- Neuromodulation Market is Determined to Reach US$ 13.0 Billion by 2024 on March 4, 2019 at 7:50 am
External neuromodulation its covers Transcranial Magnetic Stimulation & Transcutaneous Electrical Nerve Stimulation. By Application Analysis this market is segmented on the basis of Chronic Pain Manag... […]
- Behavioral Health on March 1, 2019 at 4:57 am
Dr. Bradley Cutler is a board-certified psychiatrist and medical director of chemical dependence programming, anxiety programming and transcranial magnetic stimulation treatment at Linden Oaks Behavio... […]
- Non-Invasive Device Gets FDA Clearance for Migraine Treatment, Prevention in Younger Patients on February 27, 2019 at 12:41 pm
Approval in pediatric patients was partly supported by data from the ESPOUSE Study The Food and Drug Administration (FDA) has granted marketing clearance for eNeura’s single-pulse transcranial magneti... […]
- Cobot, a New Robot, Approved for Transcranial Magnetic Stimulation Coil Positioning on February 27, 2019 at 8:35 am
Axium Robotics, a company based in Strasbourg, France, has received European and U.S. regulatory approvals for its TMS-Cobot TS MV, a robotic arm specifically developed to position the treatment coil ... […]
via Bing News